-

Toragen, Inc. Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer

Toragen is primarily focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)

— No safety issues identified in Cohort 1—

— Now proceeding to Cohort 2, for which patients have been identified —

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being conducted in two parts: a dose escalation part and dose expansion part. The dose escalation consists of five Cohorts of three to six patients. The dose expansion will begin in parallel, if Cohorts 1 and 2 of the escalation part are observed to be safe and well-tolerated and will be one dose level lower than the highest dose observed to be safe and well-tolerated in the dose escalation in combination with a PD-1 checkpoint inhibitor.

“There is a critical unmet medical need for treatments against HPV-associated cancers,” said Dr. Sandra Coufal, Toragen’s CEO. “The current treatments for these cancers are limited and we are thrilled for patients to have Toragen’s clinical trial as an option. Although preliminary, and only Cohort 1, we have seen favorable safety and tolerability data and look forward to continuing to add patients to our trial.”

About Toragen

Toragen, a clinical-stage biotechnology company, is targeting the root cause of virally induced cancers. https://toragen.com.

Contacts

Toragen, Inc.
Cheryl M. Collett
CFO
ccollett@toragen.com

Toragen Inc.


Release Versions

Contacts

Toragen, Inc.
Cheryl M. Collett
CFO
ccollett@toragen.com

Social Media Profiles
More News From Toragen Inc.

Toragen, Inc. Provides Update on Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® in Patients with Stage 4 HPV-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from its Phase 1 trial of TGN-S11, a small molecule inhibitor of the human papillomavirus (HPV) E5 oncogene protein, in patients with cancers associated with HPV. This Phase 1 trial was an open-label, non-randomized study in multiple cohorts of patients with relapsed, resistant,...

Toragen, Inc. Provides Update on Data from Ongoing Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® (pembrolizumab) in Patients with Stage 4 Human Papillomavirus-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc. provides update on data from its ongoing Phase 1 Clinical Trial of TGN-S11 in patients with Stage 4 HPV-associated cancers....

Toragen, Inc. Announced Positive Safety Data Update from Cohort 2 and the Initiation of its Dose Expansion of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 2 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being co...
Back to Newsroom